Background: The current treatment regimen for ovarian stimulation in Intracytoplasmic sperm injection (ICSI) patients is daily injections of Gonadotropins. Recombinant DNA technologies have produced a new recombinant molecule that is a long-acting Follicle Stimulating Hormone (FSH), named corifollitropin alfa. A single injection of long-acting FSH can replace seven daily FSH injections during the first week of controlled ovarian stimulation (COS) and can make assisted reproduction more patients-friendly. There is limited data with different results in this area. Objective: To compare the effectiveness of long-acting FSH vs. daily r-FSH in terms of pregnancy and safety outcomes in women undergoing ICSI cycles. Materials and Methods: In this clinical trial study, 109 women who were the candidates for ICSI at azzahra hospital were divided in two groups. The first group received 150 units of daily Gonal-f from second or third day of menstruation. The second group received a 150IU corifollitropin alfa on the second or third day of mensuration, and the treatment continued from day eighth of stimulation with Gonal-f based on the ultrasound finding. Both the groups received GnRH antagonist from fifth day of stimulation. Two groups were compared in terms of number of dominant follicles, number of oocytes, stimulation duration, total number of embryos, number of transferred embryos, and success rate of pregnancy. Results: No significant difference was found between the two groups in terms of stimulation duration, number of follicles, number of oocytes, total number of embryos, and number of transferred embryos. Moreover, pregnancy outcomes including chemical pregnancy rate (positive pregnancy test), clinical pregnancy rate (detection of fetal heart), the rate of ovarian hyper-stimulation syndrome, multiple-pregnancy, ectopic pregnancy, and miscarriage didn't have a significant difference between the two groups. Conclusion: As corifollitropin alfa was as effective as r-FSH, it could be used as an alternative to ovulation stimulation method in patients undergoing ICSI.
Introduction
Assisted reproductive techniques (ART), such as in vitro fertilization (IVF)/Intracytoplasmic sperm injection (ICSI) are very useful in infertile couples in order to achieve desired fertility outcome, where ovulation stimulation is the prerequisite for using these methods. Different methods are used for ovulation stimulation, and each of them has some advantages and disadvantages (1) . The most common method used in this regard is a daily injection of gonadotropins for ovulation stimulation (2) . Accordingly, much effort has been made in recent years to simplify the IVF therapeutic methods in order to decrease the burden imposed on the patient and to prevent the pregnancy loss after using ART through developing a high-quality method that is patient-friendly for ovulation stimulation (3) (4) (5) . Great number of researchers have recommended using corifollitropin alfa (long-acting Follicle-stimulating Hormone (FSH)) because of bioactivity profile (6) . A single injection of longacting FSH (corifollitropin alfa) could be an alternative for daily injections of FSH during the first wk. of ovulation stimulation, highly favored and welcomed by the patients (7) . Long-acting impacts of this recombinant drug (corifollitropin alfa) are related to coupling of carboxy-terminal peptide of beta chain of human chorionic gonadotropin to FSH (8, 9) . Other advantage of this drug is achieving the peak of serum concentration in the shortest time, speeding up its effect on ovarian stimulation (10) . Accordingly, it is able to stimulate the ovulation and follicular growth by injecting a single dose of corifollitropin alfa in the first wk. of the treatment cycle. Therefore, the reduced number of injections is considered as one of its advantages (11, 12) .
As this drug is welcomed by patients, and given the reduced psychological stress and the number of referrals, many studies have been carried out on corifollitropin alfa by researchers in terms of its effectiveness, factors affecting the response, used dose, and people who meet the criteria to receive this drug. However, there is no theoretical agreement in this regard, and therefore further studies are required to bring out clear results (7, 6, 11, 12) . Accordingly, this study was carried out to compare the impact of corifollitropin alfa and Gonal-f in infertile patients treated by ART who were referred to an infertility center in Iran.
Materials and Methods

Study population
This research is a clinical trial study that was carried out on patients who were candidate for ICSI. Women were randomly assigned to corifollitropin alfa or Gonal-f groups. 
Ovarian stimulation
Transvaginal ultrasound was used for all participants on the second or third day of menstruation 
Ultrasound assessment of follicular development
As mentioned before, the 1 ultrasound was done on the 2 or 3 day of cycle and after that in 5 ℎ day of stimulation. Then, serial ultrasounds were done based on patient's response to ovarian stimulation.
Outcome measures
The 
Sample size
The sample size was calculated based on the reported fertility success rates of 41% with recom- 
Ethical consideration
After approving the project by Ethics Committee of the University of Medical Sciences, IR and registering it in the Iranian Clinical Trial Database, IR, the sampling process was initiated. The methodology of the study was explained to all participants and the consent to participate in the study was obtained through a consent form filled by each one of them.
Statistical analysis
Data were analyzed using SPSS software (Statis- In this study, 109 women participated, of which, 55 were assigned to Gonal-F group and 54 to corifollitropin alfa group (Figure 1 ).
Results
In this study, the two groups had similar mean age, BMI, and also they were similar in terms of infertility duration, infertility type, and infertility cause. The main characteristics of the patients in two groups are illustrated in (Table III) . However, 100 μg long-acting FSH was prescribed for patients under 60 kg, while 150 μg of longacting FSH was prescribed for those who were above 60 kg, and the number of subjects were not same in the two groups (26 subjects in the longacting group versus 106 subjects in the daily Gonalf injection group), making it difficult to compare findings of the two studies (13) .
Discussion
On the other hand, other studies have been carried out whose findings are different from the findings of the present study, and it has been stated that long-acting FSH has been effective in ovulation stimulation and fertility outcomes in comparison to the Gonal-F method. However, the design of majority of these studies was different from that of the present study in terms of population size and subjects participating in the study (17) (18) (19) (20) In the current study, the number of multiplepregnancy was slightly higher, but it was not statistically significant. However, further studies with larger sample size should be carried out in order to make conclusion more decisively in this regard. In another study, completely contradictory findings with the present study and previous studies were reported, which questioned the effectiveness of long-acting FSH. It suggests that long-acting FSH does not have the required effectiveness for ovulation stimulation and it cannot be a good alternative to Gonal-F. Siristatids found that live birth rate in the long-acting FSH group was lower than that in the previous protocol, but other parameters such as clinical pregnancy, abortion, and secondary complications were same in the two groups (22) .
Given the different studies and obtaining contradictory results, a number of studies examined the factors involved in the response to the treatment to justify these differences. Some of these factors predicting the response to treatment effectively in long-acting FSH are the blood level of the antiMullerian hormone, the number of antral follicles, and the age and length of the menstrual cycle, which can weaken or exacerbate response to treatment (23, 24) . As different communities were studied in various studies and different results were obtained, one cannot make decisive conclusion in this regard. However, based on the majority of studies conducted in this regard, long-acting FSH can be introduced as an appropriate alternative to Gonal-f if those individuals are selected who meet the inclusion criteria. However, it is recommended that more studies be carried out with higher sample sizes to investigate the effectiveness of the factors affecting it.
Conclusion
Considering the fact that frequent injections of daily Gonal-F increase the risk of incorrect injection and it can affect the IVF outcome, using a drug with fewer injections and a single dose can resolve this problem. On the other hand, frequent injections increase the patients' stress and it can affect the treatment process and IVF outcome. Thus, corifollitropin alfa can be a good alternative for frequent injections. However, a study with wider dimensions and with larger sample size should be performed for better analysis and investigation.
